MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
12.18
-0.19
-1.50%
Opening 14:33 09/26 EDT
OPEN
12.34
PREV CLOSE
12.36
HIGH
12.56
LOW
12.08
VOLUME
842.96K
TURNOVER
5.41M
52 WEEK HIGH
19.99
52 WEEK LOW
7.61
MARKET CAP
2.26B
P/E (TTM)
-10.6378
1D
5D
1M
3M
1Y
5Y
BioCryst Pharmaceuticals promotes Sheridan to development chief
BioCryst Pharmaceuticals (NASDAQ:BCRX) <a href="https://s...
Seekingalpha · 09/14 20:23
BioCryst Pharmaceuticals Names Chief Medical Officer
BioCryst Pharmaceuticals Names Chief Medical Officer
MT Newswires · 09/14 16:21
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 17 newly-hired employees stock options to purchase an ag...
GlobeNewswire · 09/06 11:00
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022 at 11:35 a.m. ET and t...
GlobeNewswire · 08/31 20:01
BioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for BioCryst’s (NASDAQ: BCRX) lead asset BCX9250 for the treatment of fibrodysplasia ossificans progressiva (FOP).
Benzinga · 08/31 12:03
BioCryst wins FDA’s Orphan Drug status for bone disorder therapy
Commercial-stage biotech BioCryst Pharmaceuticals, Inc. (NASDAQ:<a href="https://seekingalpha.com/symbol/BCRX?utm_medium=referral&utm_source=webull.com" title="BioCryst Pharmaceuticals, Inc." target="_blan...
Seekingalpha · 08/31 11:34
BRIEF-FDA Grants Orphan Drug Designation For Biocryst’S Alk-2 Inhibitor
BRIEF-FDA Grants Orphan Drug Designation For Biocryst’S Alk-2 Inhibitor
Reuters · 08/31 11:17
FDA Grants Orphan Drug Designation For BioCryst's ALK-2 Inhibitor, BCX9250, For Treatment Of Fibrodysplasia Ossificans Progressiva
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for BCX9250 for the treatment of fibrodysplasia ossificans
Benzinga · 08/31 11:11
More
About BCRX
BioCryst Pharmaceuticals, Inc. (BioCryst) is a commercial-stage biotechnology company that discovers small-molecule medicines. The Company focus on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years and older. BioCryst has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 (ALK-2) inhibitor for the treatment of fibrodysplasia ossificans progressiva, and Galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza.

Webull offers kinds of BioCryst Pharmaceuticals Inc stock information, including NASDAQ:BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.